Air pollution is a drag for renewable energy. Dust and other sky-darkening air pollutants slash solar energy production by 17 to 25 percent across parts of India, China and the Arabian Peninsula, a new study estimates. The haze can block sunlight from reaching solar panels. And if the particles land on a panel’s flat surface, they cut down on the area exposed to the sun. Dust can come from natural sources, but the other pollutants have human-made origins, including cars, factories and coal-fired power plants.
Scientists collected and analyzed dust and pollution particles from solar panels in India, then extrapolated to quantify the impact on solar energy output in all three locations. China, which generates more solar energy than any other country, is losing up to 11 gigawatts of power capacity due to air pollution, the researchers report in the Aug. 8 Environmental Science & Technology Letters. That’s a loss of about $10 billion per year in U.S. energy costs, says study coauthor Mike Bergin of Duke University. Regular cleaning of solar panels can help. Cleaning the air, however, is harder.
Sea stars and their relatives eat, breathe and scuttle around the seafloor with tiny tube feet. Now researchers have gotten their first-ever look at similar tentacle-like structures in an extinct group of these echinoderms.
It was suspected that the ancient marine invertebrates, called edrioasteroids, had tube feet. But a set of unusually well-preserved fossils from around 430 million years ago, described September 13 in Proceedings of the Royal Society B, provides proof.
Usually, when an echinoderm dies, “the tube feet are the first things that go,” says Colin Sumrall, a paleobiologist at the University of Tennessee, Knoxville who wasn’t part of the study. “The thing that’s so stunning is that they didn’t rot away.” An abundance of soft-bodied creatures from the Silurian Period, which lasted from 444 million to 419 million years ago, are preserved in a fossil bed in Herefordshire, England. The edrioasteroids found in this bed were probably buried alive by volcanic ash, entrapped before their soft tissues could break down, says study coauthor Derek Briggs, a paleontologist at Yale University. Decaying tissue then left a void that was filled in by minerals, which preserved the shape of the appendages. Briggs and his collaborators slowly ground three fossils down, taking pictures layer-by-layer to build up a three-dimensional view. The specimens are a new genus and species, the analysis revealed. Unlike relatively flat sea stars and sand dollars, the species — dubbed Heropyrgus disterminus — had a conical body about 3 centimeters long. Its narrower end anchored in the seabed. The other end sported a set of five plates partially covering dozens of tube feet arranged in a pentagonal ring. Today’s echinoderms use hydraulic pressure in a water vascular system to extend and retract their tube feet, which serve a variety of roles. The feet can help animals pull in tiny particles of food, filter water or gases, and even inch along the seafloor. Based on the placement of H. disterminus’s tube feet (and the fact that it’s stuck in one place), the animal probably used the appendages mostly for feeding and gas exchange, Briggs suggests. The fossils didn’t preserve the internal tubing that hooks up to the tube feet, but Briggs’ team thinks that it’s a series of canals arranged like spokes connected to a wheel hub.
Sumrall isn’t surprised that this edrioasteroid had tube feet. “It’s exactly what we would have expected,” he says. But all other preserved tube feet to date come from classes of echinoderms that still have living relatives today. Edrioasteroids are less closely related to modern echinoderms, so this find broadens the range of species that scientists know sported the structures.
H. disterminus does have a few surprises, though: Its tube feet are found in two sets, in an arrangement not seen in any other echinoderms. And while it has five-point symmetry in its fleshy top part (like most other echinoderms), that transitions to eight-point symmetry in its long, columnar body.
For certain HIV antibodies, having a buddy or two makes a big difference in the fight against the virus.
Combining the antibodies, called broadly neutralizing antibodies, may stop more strains of HIV than any single one can do alone, two new studies suggest. A “triple-threat” antibody molecule can bind to three different spots on the virus, researchers report online September 20 in Science. In Science Translational Medicine, a second team describes a cocktail of two single antibodies that each target a different region of the virus. Both methods prevented infection from multiple strains of an HIV-like virus in monkeys. “We have known for many years that broadly neutralizing antibodies are extremely powerful antibodies,” says molecular biologist Nancy Haigwood of the Oregon Health & Science University in Portland, who was not involved in either study. Using more than one of these antibodies “is the most promising approach” to block HIV infection in humans because it offers more coverage, she says.
This extra coverage is needed because HIV is a master of mutation. “It’s really adopted every bit of what I would call molecular trickery to outwit our immune system, and it’s a constant battle,” says Gary Nabel, coauthor of the study in Science and chief scientific officer of Sanofi in Cambridge, Mass. The immune system keeps trying to recognize parts of the virus, but mutations in the virus can alter those sites. “You really want to have this broadside attack against the virus that hits multiple targets,” he says.
Broadly neutralizing antibodies are powerful because they can bind to multiple strains of HIV (SN: 8/19/17, p.7). The antibodies stop HIV from getting into cells to infect them. Still, “there is no single antibody” that can block all strains, says virologist Dan Barouch of Beth Israel Deaconess Medical Center in Boston.
Barouch and colleagues tackled the issue by mixing two of the antibodies together. The researchers divided 20 rhesus monkeys into four groups, giving one group the cocktail, two groups the individual antibodies and one group a saline solution with no antibodies. A day later, all of the monkeys were exposed to a mix of two simian-human immunodeficiency virus, or SHIV, strains. The outer protein that surrounds HIV, where antibodies bind, is the same in SHIV. None of the five animals that received the antibody cocktail became infected, while all of the other animals did, the researchers report in Science Translational Medicine.
Nabel and colleagues took a different tack: They developed a molecule that combines the binding talents of three antibodies into one. The researchers tested their “tri-specific” antibody in rhesus monkeys, giving eight animals the trio antibody while two other groups each received just one of the broadly neutralizing antibodies that inspired the molecule. The animals were exposed to a mix of SHIV strains five days later. Of the 16 monkeys in the solo antibody groups, 11 developed infections. None of the eight animals dosed with the trio antibody did. Both teams’ antibody approaches “show impressive protection against a combination of viruses, suggesting that they would be effective” against diverse HIV strains in humans, Haigwood says.
Virologist David Margolis of the University of North Carolina School of Medicine in Chapel Hill notes that the approaches are most likely to have preventative potential, but they also may be therapeutic. The antibody combinations might “replace oral antiretroviral therapy, or stand in for oral therapy in medical situations where pills cannot be taken,” he says.
The next step for both methods is to test the combination antibodies in people, the authors say. Whether the strategy is most effective as a preventative measure, treatment or both, the papers suggest that “to achieve optimal protection in humans,” multiple antibodies or antibody targets are going to be needed, Barouch says.
The 2011 tsunami that devastated Japan’s coast cast an enormous amount of debris out to sea — way out. Japanese marine life took advantage of the new floating real estate and booked a one-way trip to America. From 2012 to 2017, at least 289 living Japanese marine species washed up on the shores of North America and Hawaii, hitching rides on fishing boats, docks, buoys, crates and other nonbiodegradable objects, a team of U.S. researchers report in the Sept. 29 Science.
Organisms that surprisingly survived the harsh 7,000-kilometer journey across the Pacific Ocean on 634 items of tsunami debris ranged from 52-centimeter-long fish (a Western Pacific yellowtail amberjack) to microscopic single-celled protists. About 65 percent of the species have never been seen in North America’s Pacific waters. If these newcomers become established, they have the potential to become invasive, disrupting native marine habitats, says study coauthor James Carlton, a marine scientist at Williams College in Mystic, Conn. Meet some of the slimiest, strangest and potentially most invasive marine castaways that took this incredible journey:
The Northern Pacific sea star (Asterias amurensis) is among the world’s most invasive species. Though this purple and yellow sea star is normally found in shallow habitats, it can live as deep as 200 meters.
Skeleton shrimp (Caprella cristibrachium and C. mutica (shown)) grasp onto algae with their strong rear claws, earning them the nickname “praying mantis of the sea.” These lanky amphipods can grow up to about 5 centimeters long and are found in the Sea of Japan. A white, brittle Bryozoan (Biflustra grandicella) that can grow as big as a basketball is already invasive in Australia. The tiny swimming larvae of these sea creatures, also known as moss animals, may live up to a week, long enough to settle in to a new habitat.
Most of the wooden Japanese debris items collected carried at least one of seven species of large wormlike mollusks called Japanese shipworms (Psiloteredo sp.). Some of the more monstrous shipworms found, which bore into everything from wooden pilings to docks, had grown to about 50 centimeters long. Five Japanese barred knifejaw fish (Oplegnathus fasciatus), also known as striped beakfish, were found trapped in the stern well of a Japanese fishing boat found beached in 2013 in Washington. These black-and-white striped fish are native to the Northwest Pacific Ocean and Hawaii. The well acted as a tide pool of sorts, sustaining the fish during their two-year journey.
The wavy-shelled slipper snail (Crepidula onyx), also known as a slipper limpet, has essentially come full circle in its journey around the Pacific Ocean. Native to the U.S. West Coast, the well-traveled snail became an invasive species in Japan, and now has returned to America on Japanese debris.
A growing band of digital characters that converse, read faces and track body language is helping humans to communicate better with one another. While virtual helpers that perform practical tasks, such as dealing with customer service issues, are becoming ubiquitous, computer scientist M. Ehsan Hoque is at the forefront of a more emotionally savvy movement. He and his team at the University of Rochester in New York create software for digital agents that recognize when a person is succeeding or failing in specific types of social interactions. Data from face-to-face conversations and feedback from professional counselors and interviewers with relevant expertise inform this breed of computer advisers.
One of Hoque’s digital helpers grooms people to be better public speakers. With words on a screen, this attentive app notes, for example, how many times in a practice talk a person says “um,” gestures inappropriately or awkwardly shifts vocal tone. With the help of Google Glass, the app even offers useful reminders during actual speeches. Another computerized helper, this one in the form of an avatar, helps people hone their job interviewing skills, flagging long-winded responses or inconsistent eye contact in practice interviews. In the works are computerized conversation coaches that can improve speech and communication skills among people with developmental conditions such as autism and mediate business meetings in ways that encourage everyone to participate in decision making.
“There has been some progress in artificial intelligence, but not much in developing emotional aspects of AI,” Hoque says. “We’re just cracking through the surface at this point.” The U.S. Department of Defense and the U.S. Army have taken notice. With their financial support, Hoque is developing avatars that collaborate with humans to solve complex problems, and digital observers that monitor body language to detect when people are lying. This is heady stuff for a 35-year-old who earned a doctoral degree just four years ago. Hoque, who was born in Bangladesh and immigrated to the United States as a teenager, did his graduate work with the MIT Media Lab’s Affective Computing research group. The group’s director, Rosalind Picard, helped launch the field of “affective computing” in the 1990s, which focuses on the study and development of computers and robots that recognize, interpret and simulate human emotions.
Hoque’s approach puts a service spin on affective computing. As a grad student, he developed software he dubbed MACH, short for My Automated Conversation coacH. This system simulates face-to-face conversations with a computer-generated, 3-D man or woman that sees, hears and makes decisions while conversing with a real-life partner. Digital analyses of a human partner’s speech and nonverbal behavior inform the avatar’s responses during a session. A simulated coach may, for instance, let a user know if smiles during an interview look forced or are mistimed. After a session, users see a video of the interaction accompanied by displays of how well or poorly they did on various interaction skills, such as keeping eye contact and nodding at appropriate times.
MACH got its start in trials that trained MIT undergraduates how to conduct themselves during interviews with career counselors. First, Hoque analyzed smiles and other behaviors that either helped or hurt the impressions job candidates left on experienced counselors in mock interviews. In a series of follow-up studies, his team developed an automated system that recognized impression-enhancing behaviors during simulated interviews. That pilot version of MACH was then put to the test. Women, but not men, who received MACH training and got feedback from their digital coach while watching videos of their initial interviews with a counselor displayed substantial improvement in follow-up interviews. MACH trainees who watched interview videos but got no feedback showed minimal improvement. Testing with larger groups of men and women is under way. As he developed MACH, Hoque consulted MIT sociologist and clinical psychologist Sherry Turkle. That was a bold move, since Turkle has warned for 30 years that, despite its pluses, digital culture discourages person-to-person connections. Social robots, in particular, represent a way for people to escape the challenges of forging authentic relationships, Turkle contends.
But she came away impressed with Hoque, whose goals she calls refreshingly modest and transparent. “His avatars will be helpers and facilitators,” she says, “not companions, friends, therapists and pretend people.”
Hoque’s approach grew out of personal experience. He is the primary caregiver for his 16-year-old brother, Eshteher, who has Down syndrome and does not speak. Eshteher can make sounds to refer to certain things, such as food, and has limited use of sign language. “I’ve spent a lot of time with him and can read what he’s experiencing, like when he’s frustrated or repentant,” Hoque says. So it’s not surprising that Hoque’s next-generation MACH, dubbed LISSA for Live Interactive Social Skill Assistance, is an avatar that conducts flexible, “getting acquainted” conversations while providing feedback on users’ eye contact, speaking volume, smiling and body movements via flashing icons.
LISSA has shown promise in preliminary tests aimed at improving the conversational chops of college students attending speed-dating sessions and individuals with autism spectrum disorders. Hoque plans to expand this technology for use with people suffering from social phobia and post-traumatic stress disorder. He’s also working on an avatar that trains doctors to communicate clearly and compassionately with patients being treated for life-threatening cancers.
Hoque’s work on emotionally perceptive avatars may eventually transform the young industry of digital assistants, currently limited to voices-in-a-box such as Apple’s Siri and Microsoft’s Cortana, says cognitive scientist Mary Czerwinski, a principal researcher at Microsoft Research Lab in Redmond, Wash. Avatar research “could lead to more natural, personable digital assistants,” Czerwinski predicts. Hoque agrees.
“In the future, we’ll all have digital, personalized assistants,” he says. If he gets his way, emotionally attuned helpers will make us more social and less isolated. That’s something to applaud — if we can manage to put down our smartphones.
One of the planet’s deadliest viruses makes an annual pass through the United States with little fanfare. It rarely generates flashy headlines or news footage of health workers in hazmat suits. There’s no sudden panic when a sick person shows up coughing and feverish in an emergency room. Yet before next spring, this season’s lethal germ will probably have infected millions of Americans, killing tens of thousands. Still, it’s often referred to as just the flu.
The influenza virus seems so normal to most Americans that only about half of us will heed those “time for your flu shot” banners that pop up at pharmacies and worksites every autumn. Those annual shots remain the best means of protection, but they must be manufactured months before flu season starts, based on a best educated guess of what strains of the virus will be circulating. That means even in a successful year, vaccine performance may not be impressive. During the 2015–2016 season, only about half of those immunized were protected, according to a study in the Aug. 10 New England Journal of Medicine. Some years’ vaccines are duds: For the 2014–2015 season, the vaccine protected only 19 percent of people who received it, based on U.S. Centers for Disease Control and Prevention data. Scientists have long worked to develop a flu shot that works better and lasts longer. But, unlike the very stable measles virus, influenza is a moving target. While only a few strains of flu virus circulate worldwide in a typical year, dozens more may exist. Each one is highly likely to mutate from year to year, with just enough shape-shifting to be unrecognizable to the body’s defenses.
Now, after years of searching, scientists believe they have better strategies to attack the parts of the virus that stay the same from year to year, offering the hope of protection across multiple seasons. The vaccines being developed in laboratories around the world “offer more promise than we’ve ever had,” says Walter Orenstein, associate director of the Emory Vaccine Center in Atlanta. And there are new creative approaches: One research group is trying to make a kind of super shot by anticipating every possible mutation a circulating virus might undergo.
“I’m optimistic we are going to get to a vaccine,” says Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, or NIAID, in Bethesda, Md. Then, you may need to heed those “time for your flu shot” messages only once. Researchers often describe the flu virus as looking like a ball with lollipops sticking out. Tucked inside the ball is RNA, which the virus needs to make copies of itself. The lollipops on the outside are proteins: hemagglutinin and neuraminidase. There are 18 different kinds of hemagglutinin and 11 kinds of neuraminidase. Each kind of flu virus is named for its particular combination of these proteins; the current forms circulating around the world are H1N1 and H3N2. Hemagglutinin attaches to human cells to launch an infection; neuraminidase is more important for spreading the virus once infection has occurred.
Flu viruses involved in human epidemics are divided into types A and B, and A viruses are sliced even further into group 1 and group 2. Influenza A, the most troublesome for vaccine scientists, travels the world among birds, pigs and humans. The bird and pig versions don’t easily infect people, but the virus is constantly mutating and even swapping genes with other influenza viruses it meets along the way. Sometimes these genetic changes create a version that allows a bird or pig flu to move directly into humans. In 2013, one called H7N9 moved into people in China (SN Online: 3/11/15). The virus has since infected more than 1,500 people. Mostly, though, the genetic changes are more subtle, with just enough alterations to evade the human immune system. Like kids with a sweet tooth, the immune system gets most excited about the top part of the hemagglutinin lollipop, and makes antibodies against it. The top is, after all, the first thing the immune system notices once the virus slips inside the nose, mouth and lungs. Every year, genetic mutations in the virus slightly change the chemical flavor of the lollipop, making it more sweet or sour than last season’s — just different enough so the immune system doesn’t recognize it. That’s why most years there’s a new flu shot.
Sometimes, in the gene shuffling with viruses in birds and pigs, the changes are so great that the flavor changes completely. Those are pandemic years, when there is so little residual immunity that a large portion of the global population falls ill from the new virus. The devastating 1918 flu, which killed an estimated 50 million people globally, was caused by such a drastic genetic shift (SN Online: 4/29/14). The most recent pandemic occurred in 2009, with the appearance of the “swine flu,” so named because the virus was first found in pigs. By one analysis, it caused between 148,000 and 249,000 deaths around the world.
Attack the stem The 2009 disaster helped provide a blueprint for some of the latest experimental vaccines. Researchers noticed that when people with swine flu developed antibodies to the virus, those antibodies did something odd: They favored the hemagglutinin stem — the stick of the lollipop. And, more important, they appeared to react broadly against two kinds of flu virus. Scientists had known that the hemagglutinin stem, or stalk, isn’t as apt to change as the lollipop top, which theoretically makes the stem a good target for a universal vaccine. But in a usual flu season, the human body isn’t inclined to make infection-fighting antibodies against the stem.
“Unfortunately, the immune system preferentially recognizes the head, and we don’t know why it does that,” says Adrian McDermott, an immunologist at NIAID. So after infection, the biggest share of antibodies flocks to the hemagglutinin head. (Neuraminidase, the bigger player in disease after infection, is a target for influenza treatments but not a major focus for vaccine development.)
But in a study reported in the Journal of Experimental Medicine in 2011, a team of scientists from Emory and elsewhere found that antibodies to the so-called swine flu behaved unexpectedly. “If you have a head that the immune system hasn’t seen, you potentially redirect to a stalk response,” McDermott says. “That was an aha! moment.” Researchers investigated further. For one study in 2012 in Frontiers in Immunology, scientists from Canada injected these stem-recognizing antibodies into mice to see if the mice were shielded from a different strain of flu. Not only were the mice protected from lethal doses of flu virus, but the protection was also in large part due to the absence of familiar antibodies against the head, the researchers found. Without the distraction of a head it recognized, the immune system seemed to rally against the stem.
Then came the what ifs: What if a vaccine produced just antibodies to the stem? Would that be enough protection? For the last few years, McDermott and others have been trying to develop vaccines made of “headless stalks” — just the sticks of the lollipops. With no head in place to hoard the immune response, the vaccine might coax the body to make enough stem-focused antibodies to protect against flu, the researchers hoped, regardless of the seasonal mutations occurring at the top.
Several groups soon found that headless stalks are difficult to make. Without the top to stabilize it, the molecular assembly tended to break apart. Two teams working independently reported in 2015 their success in keeping the stalk in one piece. NIAID scientists and their partners held the stalks together by anchoring them to the protein ferritin, which can assemble itself into nanoparticles. In a study in Nature Medicine, the team reported that vaccinated mice and ferrets appeared to be protected from dying of the H5N1 bird flu after receiving the vaccine, even when they developed symptoms. Unvaccinated mice and ferrets died.
The second team, from the Janssen Center of Excellence for Immunoprophylaxis in Leiden, the Netherlands, and the Scripps Research Institute in La Jolla, Calif., glued the stalk together by creating a series of genetic mutations at its top. In Science, the researchers reported that the vaccine reduced the symptoms of flu in vaccinated monkeys.
“We realized that the stem has much less variability than the head, and then we developed the capability to use it for a possible vaccine,” says Fauci, commenting on both efforts. “These were two important things that came together.”
Despite progress, these stalk-focused vaccines haven’t yet been put to human tests that would show whether they could protect broadly against many mutations of flu circulating annually, which is the ultimate test. And some stalk-directed antibodies might be better than others. In July in Science Immunology, McDermott and colleagues reported that the stalk antibodies against group 2 of the A viruses appear to be more broadly effective than those against group 1 viruses.
Other researchers have stabilized the stalk by attaching a new hemagglutinin head — a lollipop flavor that the human immune system has never tasted. In this case, researchers from the Icahn School of Medicine at Mount Sinai in New York City took tops from two flu strains that circulate only in birds, and connected each one to a human hemagglutinin stalk. This experimental vaccine consists of two doses. The first dose prompts the immune system to make antibodies against the stalk with the first top, and a second dose produces a second round of antibodies against the stalk with the second top. The idea is that the abundance of stem-focused antibodies — amplified from the two shots of vaccine — will come to the rescue during a natural infection from a virus that possesses a third, totally different head. “The human immune system will try to find something it has seen before,” says Peter Palese, chairman of microbiology at Mount Sinai. In theory, the only antibodies in play will be the ones responding to the parts of the stalk that the immune system recognizes, known as the “conserved domains.”
“The $64,000 question,” according to Palese: “Will the immune response to these conserved domains be enough to elicit a broad immune system reaction?”
In 2016, Palese and colleagues described a test of the vaccine in the Journal of Virology. Six ferrets given the two doses were housed with six ferrets infected with H1N1 flu. Within 10 days, the vaccinated animals had become infected but had no symptoms or signs of being able to easily spread virus to others. A report in June in the same journal described tests of the vaccine in mice against influenza B viruses; the animals were protected from normally lethal doses of flu.
What’s not known is whether the stem-focused antibodies are enough to protect people from all virus variants. The vaccine from the Mount Sinai researchers is entering the first human safety trials with drugmaker GlaxoSmithKline.
Unhide and seek Another approach incorporates proteins that don’t tend to mutate like the hemagglutinin head but are hidden from the immune system under normal circumstances. When these proteins are made visible to types of white blood cells called T cells, the immune system wakes up. T cells don’t make antibodies, but certain T cells hold on to a memory of foreign molecules seen before. When these pre-programmed T cells recognize an infection, they destroy the invader.
This work began in the 1990s, when researchers at the Weizmann Institute of Science in Rehovot, Israel, set out to find parts of the virus that remain unchanged from year to year. The team identified stable regions in three proteins — hemagglutinin, plus one from the virus membrane and one from the virus core. In 2003, a company called BiondVax Pharmaceuticals formed to develop and test, in humans, an experimental vaccine that takes these proteins and packages them in a way that the immune system can recognize them.
So far, almost 700 volunteers have participated in six small trials, all of which showed signs of a lasting immune response among most volunteers. Writing in February in Vaccine, the researchers reported that the stored serum of elderly volunteers who received the vaccine in 2011 showed an immune response to new strains of flu that were circulating three years later. The company is starting larger trials to see if the vaccine can actually protect people from getting sick. Out of many, one Other experimental vaccines take a different approach. Rather than relying on precision to hit a narrow target, microbiologist Ted Ross and colleagues at the University of Georgia in Athens are attempting to cast a wide net. The researchers are taking hemagglutinin mutations from every flu strain that has ever circulated, dumping them into a kind of scientific blender and attaching them to particles that can form the basis of a vaccine.
“The question we asked is, how can we make a vaccine against a strain we don’t even know exists?” Ross says. The technique he uses is called COBRA for computationally optimized broadly reactive antigen. A computer compiles all seemingly possible genetic iterations of a particular flu type — in this case H1N1 — and then bundles them into one molecule. It’s kind of like taking every novel in your local library and combining them into one giant book.
Last year in the Journal of Virology, Ross and colleagues described a COBRA-derived vaccine that represented almost all forms of H1N1 that have been around for the last 100 years. The vaccine protected mice against infection from strains of H1N1 that the mice had never been exposed to. “We took a bunch of different hemagglutinins and mixed them into one hemagglutinin molecule,” Ross says. “It protected against any strain of H1N1 we could throw at it.”
The study caught the attention of vaccine maker Sanofi Pasteur, which plans to test the vaccine in clinical trials. Ross’ lab is now using the same strategy to develop a vaccine against H3N2 strains, the other dominant kind of flu circulating around the world. Same approach, different library.
Meanwhile, the virus isn’t waiting around. Based on the heavy flu season in the Southern Hemisphere, some experts are predicting this year’s epidemic could be severe. It’s still too early to know whether the current vaccine will provide good protection, but someday, a super shot may remove the guesswork altogether.
A gigantic emergency arresting gear system, capable of stopping the largest four-engined jet aircraft without discomfort to passengers, is being developed for the French Ministry of Transportation. The system consists of a nylon net … which engages the aircraft for the full width of its wingspan. Net and airplane are brought to a slow stop by energy absorbing devices located along the sides of the runway. — Science News, September 28, 1967 Catching commercial airliners in giant nets never took off. However, aircraft carriers have deployed nets since 1931 for emergency landings. In modern versions, nets are linked to energy-absorbers below deck to help bring a plane to a safe stop. Today’s net systems are a big improvement over the original barricade: Aviation pioneer Eugene Ely first landed an airplane on a ship, the USS Pennsylvania, in 1911. His landing relied on sandbag-secured ropes across the deck plus a canvas awning between the plane and the sea. Editor’s note: This story was corrected on November 6, 2017. The nets used on the aircraft carriers to arrest airplanes were not made of nylon until after nylon became available in 1935.
The parasite can bring about dysentery — a miserable (and occasionally deadly) mixture of diarrhea, cramps and fever. Scientists have now uncovered traces of the giardia parasite in the remains of two roughly 2,600-year-old toilets once used by the wealthy denizens of Jerusalem. The remains are the oldest known biological evidence of giardia anywhere in the world, researchers report May 25 in Parasitology.
The single-cell parasite Giardia duodenalis can be found today in human guts around the planet. This wasn’t always the case — but working out how pathogens made their debut and moved around is no easy feat (SN: 2/2/22). While some intestinal parasites can be preserved for centuries in the ground, others, like giardia, quickly disintegrate and can’t be spotted under a microscope. In 1991 and 2019, archeologists working at two sites in Jerusalem came across stone toilet seats in the remains of mansionlike homes. These “were quite posh toilets” used by “swanky people,” says Piers Mitchel, a paleoparasitolgist at the University of Cambridge.
The original excavators of soil taken from beneath the seats of these toilets glimpsed traces of roundworm and other possible intestinal parasites in soil samples put under a microscope. Mitchel and his colleagues built on this analysis by using antibodies to search for the remains of giardia and two other fragile parasites in the millennia-old decomposed feces under both seats.
There was “plenty of doubt” that giardia was around in Jerusalem at the time because it’s so hard to reconstruct the movement of ancient disease, Mitchel says.
But the find hints that it was a regular presence in the region, says Mattieu le Bailly, a paleoparasitolgist at the University Bourgogne Franche-Comté in Besançon, France, who was not involved in the study.
The idea that a pathogen like giardia, which spreads via contaminated water and sometimes flies, existed and was possibly widespread in ancient Jerusalem makes a lot of sense, Mitchel says, given the hot, dry, insect-ridden climate around the Iron Age city.
Some ants have figured out how to keep from getting lost: Build taller anthills.
Desert ants that live in the hot, flat salt pans of Tunisia spend their days looking for food. Successful grocery runs can take the insects as far as 1.1 kilometers from their nests. So some of these ants build towering hills over their nests that serve as a landmark to guide the way home, researchers report in the July 10 Current Biology. “I am surprised and fascinated that ants have visual acuity at the distances implied in this work,” says ecologist Judith Bronstein of the University of Arizona in Tucson who wasn’t involved in the new study. It “also implies that ants regularly assess the complexity of their local habitat and change their decisions based on what they conclude about it.”
Desert ants (Cataglyphis spp.) use a navigation system called path integration, relying on the sun’s position and counting their steps to keep track of where they are relative to their nest (SN: 1/19/17). But this system becomes increasingly unreliable as distance from the nest increases. Like other types of ants, desert ants also rely more generally on sight and smell. But the vast, almost featureless salt pans look nearly the same in every direction.
“We realized that, whenever the ants in salt pans came closer to their nest, they suddenly pinpointed the nest hill … from several meters distance,” says Markus Knaden, a neuroethologist at Max Planck Institute for Chemical Ecology in Jena, Germany. “This made us think that the hill functions as a nest-defining landmark.”
So Knaden and colleagues captured ants (C. fortis) from nests in the middle of salt pans and from along their shorelines. Only nests from the salt pan interiors had distinct hills, which can be up to 40 centimeters tall, whereas the hills on shoreline nests were lower or barely noticeable. Next, the team removed any hills and placed the captured insects some distance away from their nests. Ants from the salt pans’ interiors struggled more than shore ants to find home. Since the shore ants were adept at using the shoreline for guidance, they weren’t as affected by the hill removal, the researchers conclude.
The team wanted to know if the ants were deliberately building a taller hill when their surroundings lacked any visible landmark. So, the researchers removed the hills of 16 salt pan nests and installed two 50-centimeter-tall black cylinders apiece near eight of them. The other eight nests were left without any artificial visual aid. After three days, the researchers found that ants from seven of the unaided nests had rebuilt their hills. But ants from only two of the nests with cylinders had bothered to rebuild.
“These desert ants already told us about path integration and step counting for orientation…. But this business of building your own visual landmark, incredible,” says entomologist John Longino of the University of Utah in Salt Lake City who wasn’t involved in the research. “Are they sitting down to a council meeting to decide whether they need a bigger landmark? Is this somehow an evolved behavior in this one desert ant species?”
For now, it’s unclear how the ants decide to build, or not to build, a hill. Interestingly, nest building is usually performed by younger ants that are not foragers yet, Knaden says, and have not experienced the difficulty in finding a nest in the absence of a hill. That means there is an exchange of information between the veteran foraging ants and their novice nest mates, he says.
Bronstein also wonders about the risks of building the taller structures. Such risks “are implied by the fact that the ants don’t build such a structure where it isn’t needed,” she says. But, “for instance, isn’t it a clear cue to ant predators that food can be found there?”
Jellyfish have gotten a bad rap. In recent years, concerns about rising jellyfish populations in some parts of the world have mushroomed into headlines like “Meet your new jellyfish overlords.” These floating menaces are taking over the world’s oceans thanks to climate change and ocean acidification, the thinking goes, and soon waters will be filled with little more than the animals’ pulsating goo.
It’s a vivid and frightening image, but researchers aren’t at all certain that it’s true. In her new book, Spineless, former marine scientist Juli Berwald sets out to find the truth about the jellyfish take-over. In the process, she shares much more about these fascinating creatures than merely their numbers. Among a few of the amazing jellyfish facts and tales throughout the book: Jellyfish have astoundingly complex vision for animals without a brain. They are also the most efficient swimmers ever studied, among the most ancient animals surviving on Earth today and some of the most toxic sea creatures (SN: 9/6/14, p. 16).
Rather than merely reciting these facts, Berwald takes readers on a personal journey, tracing how life pulled her away from science after she earned her Ph.D. — and how jellies brought her back. Through the tale of her experiments with a home jellyfish aquarium, she explains jelly biology, from the amazing shape-shifting properties of the mesoglea that forms a jellyfish’s bulk to why so many species are transparent. As she juggles family life with interviews with the world’s leading jellyfish researchers, Berwald also documents her travels to places around the globe where jellyfish and humans intersect, such as Israel’s coral reefs and Japan’s fisheries. The answer to the question of whether jellyfish populations are on the rise ultimately lies at this intersection, Berwald finds. Marine scientists are split on whether populations are increasing globally. It depends on which data you include, and it’s possible that jellyfish numbers fluctuate naturally on a 20-year cycle. What is clear is that in coastal areas around the world, people have unwittingly created spawning grounds for huge numbers of jellyfish simply by building docks and other structures that quickly multiplying jellyfish polyps can attach to.
In the end, Berwald says, jellyfish became a “vehicle for me to explore the threats to the ocean’s future. They’re a way to start a conversation about things that can seem boring and abstract — acidification, warming, overfishing and coastal development — but that are changing our oceans in fundamental ways.” And that’s more interesting than an ocean full of goo.
